Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion
1.7.2026 13:01:00 EEST | Business Wire | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/
Dr. Hubert Scholze, Chief Business Officer, Rezon Bio
As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution.
His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated biologics CDMO offering, expanding its global commercial footprint while investing in the capabilities, expertise and partnerships needed to support biosimilars and novel biologics programs from early development to commercial manufacturing.
Dr. Hubert Scholze brings more than 25 years of experience spanning biologics manufacturing, operations and global business development across the pharmaceutical and CDMO industries. Prior to joining Rezon Bio, he led Global Business Development for Catalent’s Core Biologics division, overseeing commercial activities for integrated mammalian drug substance and sterile drug product development and manufacturing services.
“Hubert brings a unique combination of manufacturing expertise, commercial leadership and a deep understanding of the biologics industry and client needs,” said Dr. Adriana Kiędzierska-Mencfeld, Chief Executive Officer (CEO) of Rezon Bio. “His leadership will strengthen how we integrate commercial strategy, scientific excellence and operational execution to deliver greater value for our clients as our organization enters the next phase of growth.”
“I am excited to join Rezon Bio at such an important moment in the company’s journey,” said Dr. Scholze. “What attracted me the most is the proven track record, strong scientific and manufacturing expertise, and talented people who are passionate about delivering for their clients. Combined with a clear ambition for international growth, this creates a strong foundation for the future. I look forward to working with our teams and clients to build long-term partnerships, expand our global presence, and help bring innovative biologic therapies to patients worldwide.”
Dr. Scholze began his career at Boehringer Ingelheim in Vienna, where he held leadership positions in biologics manufacturing, including Unit Head of a large-scale microbial fermentation facility and Manufacturing Director. After several years in manufacturing, he transitioned into sales and business development, taking on roles of increasing responsibility at leading pharmaceutical and biologics CDMO organizations, including Aenova Group and Catalent. Throughout his career, he has partnered with emerging biotech companies and global pharmaceutical organizations, supporting programs from early-phase development through large-scale commercial manufacturing.
Hubert Scholze, PhD, holds a doctorate in Biochemistry from University of Technology Graz, Austria.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
For more information, please visit: https://rezonbio.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260701630118/en/
Contacts
Media Contact:
Loukiani Chatzinasiou
loukiani.chatzinasiou@rezonbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 14:00:00 EEST | Press release
Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701144267/en/ Azalea Vision Co-founder and CTO Andrés Vásquez Quintero undergoing an on-eye evaluation of the ALMA smart contact lens. Beyond the funding, the award is a strong external endorsement of Azalea’s technology and long-term vision. Built on its proprietary smart contact lens platform, Azalea’s smart lens is designed to
Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 13:34:00 EEST | Press release
Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval of ChIQ™, we continue to strengthen the presence of our saypha® portfolio in the United States," said Andreas Prinz, Chief Executive Officer of Crom
CoStar Group Invests in Wikicasa, Italy’s Agent-Backed Real Estate Marketplace1.7.2026 13:00:00 EEST | Press release
CoStar Group, Inc. (NASDAQ: CSGP), a global leader in online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, today announced an investment in Wikicasa, Italy’s agent-backed real estate marketplace. The transaction will result in CoStar Group acquiring an approximately 30% stake in Wikicasa. Wikicasa’s shareholder base includes Italy’s leading real estate agencies - including Tecnocasa Group, Gabetti Group, RE/MAX Italy, and Tempocasa. Wikicasa.it is an agent-driven platform that brings together leading real estate professionals across Italy to deliver a high-quality, data-rich marketplace of over 600,000 listings, more than 100,000 of which are commercial. It provides consumers with comprehensive property listings while equipping agents with modern data and intelligence tools to market properties and connect with buyers, sellers, landlords and tenants. CoStar Group operates some of the world’s leading online residential and comme
Forrester Announces The Conference Agenda For B2B Forum EMEA 20261.7.2026 12:46:00 EEST | Press release
Forrester (Nasdaq: FORR) today announced the full conference agenda for its B2B Forum EMEA 2026, taking place 28–29 September 2026 in London. Centered on the theme, “Hello, GTM Singularity,” the event will bring together marketing, sales, product, customer success, and revenue leaders to address the collapse of traditional go-to-market (GTM) models. According to Forrester, approximately nine in 10 business buyers now use genAI or conversational search in the buying process. As AI-led discovery, changing buying behaviours, and increasingly complex buying networks continue to disrupt how customers discover, evaluate, and purchase solutions, organisations must integrate their GTM approach as a unified system that builds visibility, preference, and trust. Designed as an intimate event for senior B2B leaders, B2B Forum EMEA 2026 will combine keynote presentations, analyst-led sessions, workshops, case studies, networking opportunities, and leadership programmes to provide attendees with pra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom